November 2025 in “Turkish Journal of Dermatology” Both baricitinib and tofacitinib effectively reduce alopecia areata severity, with tofacitinib showing more improvement over longer use.
October 2025 in “Clinical Cosmetic and Investigational Dermatology” Targeting specific cell interactions may help treat skin fibrosis.
September 2025 in “Frontiers in Cell and Developmental Biology” Retinoic acid may help heal skin without scars by reducing fibrosis and supporting skin regeneration.
September 2025 in “Journal of Drug Delivery and Therapeutics” Targeting hair follicles can effectively promote hair growth and treat hair disorders.
October 2024 in “Irish Journal of Medical Science (1971 -)” Continuous glucose monitoring and GLP-1 receptor agonists improve diabetes management, but personalized care and education are crucial.
Personalized care and evidence-based treatments are crucial for managing skin and hair conditions.
May 2024 in “Frontiers in Immunology” Type-2 immunity may influence skin diseases and could be targeted for treatment.
February 2024 in “International neuropsychiatric disease journal” Alopecia areata severely impacts quality of life, mental health, and work productivity.
February 2024 in “PloS one” Tofacitinib and adalimumab are promising treatments for cicatricial alopecia with few side effects.
January 2024 in “Clinical, cosmetic and investigational dermatology” Dermatologists should customize cosmetic treatments for dark-skinned patients to minimize risks and complications.